TRIPODD: a novel fluorescence imaging platform for in situ measurement of drug distribution and proteomic therapeutic response

Personalized molecularly targeted therapy has largely not lived up to its promise of providing curative therapies due to a lack of durable therapeutic response driven by a lack of drug target engagement (i.e. sublethal drug delivery to the tumor) and cell signaling reprogramming as a mechanism of acquired resistance. To simultaneously measure both of these factors, we have developed and optimized a fluorescence imaging platform, Therapeutic Response Imaging through Proteomic and Optical Drug Distribution (TRIPODD), resulting in the only methodology capable of simultaneous quantification of single-cell DTE and protein expression with preserved spatial context within a tumor.